Trehalose ( DrugBank: Trehalose )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2
113	筋ジストロフィー	1

2. 筋萎縮性側索硬化症

---

臨床試験数 : 624 /  薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05136885 (ClinicalTrials.gov)	February 2022	14/11/2021	HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose	HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose	Amyotrophic Lateral Sclerosis	Drug: SLS-005;Drug: Matching Placebo	Merit E. Cudkowicz, MD	Seelos Therapeutics, Inc.	Not yet recruiting	18 Years	N/A	All	160	Phase 2/Phase 3	NULL
2	NCT04297683 (ClinicalTrials.gov)	July 14, 2020	3/3/2020	HEALEY ALS Platform Trial - Master Protocol	HEALEY ALS Platform Trial	Amyotrophic Lateral Sclerosis	Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose	Merit E. Cudkowicz, MD	Massachusetts General Hospital	Recruiting	18 Years	N/A	All	800	Phase 2/Phase 3	United States

113. 筋ジストロフィー

---

臨床試験数 : 622 /  薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04226924 (ClinicalTrials.gov)	June 15, 2017	15/7/2019	Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose	A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Trial of Trehalose for the Treatment of	Oculopharyngeal Muscular Dystrophy	Drug: Trehalose	Bioblast Pharma Ltd.	NULL	Withdrawn	50 Years	70 Years	All	0	Phase 2	Canada